{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:07:00Z","timestamp":1784696820729,"version":"3.55.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Relapse of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is associated with poor prognosis and remains the most common cause of treatment failure following allogeneic hematopoietic stem cell transplantation (alloHSCT). Over the past two decades, hypomethylating agents (HMAs), particularly azacytidine, have evolved from an experimental approach to the current therapeutic backbone of relapse therapy following alloHSCT, although future treatment paradigms may further evolve with emerging targeted and immunotherapeutic approaches. The RELAZA studies demonstrated that preemptive therapy with azacytidine in molecular relapse can significantly delay the onset of hematologic relapse. However, sustained disease control generally requires additional immunological mechanisms. Against this backdrop, the combination of azacytidine\u2014either alone or in combination regimens\u2014with donor lymphocyte infusions (DLI) has been established as a successful salvage strategy. Numerous studies have consistently shown over the years that a low disease burden, molecular rather than hematological relapse, and a longer interval between transplant and relapse are associated with better response rates and prolonged survival. This underscores the great importance of MRD monitoring for enabling early intervention. Prognostic models such as the APSS-R score incorporate these factors. Additionally, the score takes into account pre-transplant therapy, thereby underscoring the importance of a biologically tailored treatment strategy to prevent the emergence of treatment-resistant clones. Recent combination therapies with targeted agents, such as FLT3 and IDH inhibitors, as well as with venetoclax or lenalidomide, are showing promising results. Future strategies will likely focus on individualized, biological1ly guided treatment approaches and a selective indication for second alloHSCT.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1895791","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:41:48Z","timestamp":1784695308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Guido","family":"Kobbe","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titus","family":"Watrin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kaprzak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Nachtkamp","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, University Hospital D\u00fcsseldorf, Heinrich Heine University, Medical Faculty","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12720","article-title":"Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia","volume":"283","author":"Craddock","year":"2018","journal-title":"J Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03670-6","article-title":"Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid Malignancies","volume":"98","author":"Schuler","year":"2019","journal-title":"Ann Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.300","article-title":"Management of relapse after allo-SCT for AML and the role of second transplantation","volume":"44","author":"Savani","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403412","article-title":"Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation","volume":"18","author":"Schmid","year":"2004","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.003","article-title":"Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine","volume":"31","author":"Graef","year":"2007","journal-title":"Leuk Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0b013e3182481113","article-title":"Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation","volume":"93","author":"St\u00f6lzel","year":"2012","journal-title":"Transplantation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2021-149081","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98962","article-title":"Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant","volume":"3","author":"Jacoby","year":"2018","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1073\/pnas.1813666116","article-title":"Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome","volume":"116","author":"Leung","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650473","article-title":"Mechanisms of action of hypomethylating agents: Endogenous retroelements at the epicenter","volume":"11","author":"Kordella","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016289118","article-title":"Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs","volume":"118","author":"Ku","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.exphem.2022.04.002","article-title":"Recurrent transcriptional responses in AML and MDS patients treated with decitabine","volume":"111","author":"Upadhyay","year":"2022","journal-title":"Exp Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074823","article-title":"The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome","volume":"98","author":"Costantini","year":"2013","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-022-00615-7","article-title":"Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients","volume":"12","author":"Grimm","year":"2022","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"418292","DOI":"10.1155\/2014\/418292","article-title":"5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity","volume":"2014","author":"St\u00fcbig","year":"2014","journal-title":"Mediators Inflammation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.35","article-title":"Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation","volume":"3","author":"Sch\u00f6nefeldt","year":"2013","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6213","article-title":"Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome","volume":"6","author":"Sohlberg","year":"2015","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02420-x","article-title":"Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression","volume":"68","author":"Montes","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1183860","article-title":"Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine","volume":"5","author":"Moudra","year":"2016","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2394-6","article-title":"Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells","volume":"143","author":"Zhou","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1314425","article-title":"Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects","volume":"6","author":"Ehx","year":"2017","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030816","article-title":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial","volume":"147","author":"Platzbecker","year":"2026","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","first-page":"255","article-title":"Perspectives of German transplant centers on the management of relapse in MDS and AML following allogeneic hematopoietic stem cell transplantation","volume":"48","author":"Schulz","year":"2025","journal-title":"Oncol Res Treat"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","volume":"45","author":"L\u00fcbbert","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1605066","article-title":"Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy","volume":"60","author":"Claiborne","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: a prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082255","article-title":"Prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Rautenberg","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221090882","article-title":"Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors","volume":"13","author":"Liberatore","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2018.02.148","article-title":"Azacitidine for relapse after allogeneic stem cell transplantation-single-center study","volume":"50","author":"Karakulska-Prystupiuk","year":"2018","journal-title":"Transplant Proc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.58","article-title":"Azacitidine as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Ozawa","year":"2019","journal-title":"Adv Cell Gene Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.949534","article-title":"Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1607-y","article-title":"Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)","volume":"92","author":"Ganguly","year":"2013","journal-title":"Ann Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann Hematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.07.005","article-title":"Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid Malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation","volume":"72","author":"Sommer","year":"2018","journal-title":"Leuk Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/jco.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.04.017","article-title":"Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia","volume":"33","author":"Safaian","year":"2009","journal-title":"Leuk Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.09.016","article-title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation","volume":"86","author":"Metzelder","year":"2017","journal-title":"Eur J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12832","article-title":"Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT","volume":"98","author":"Rautenberg","year":"2017","journal-title":"Eur J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-45082017rc3784","article-title":"Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases","volume":"15","author":"Campregher","year":"2017","journal-title":"Einstein (Sao Paulo)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25805","article-title":"Azacitidine and sorafenib therapy in a pediatric patient with refractory acute myeloid leukemia with monosomy 7 and somatic PTPN11 mutation","volume":"63","author":"Dahl","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.10.002","article-title":"Treatment of post-transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy","volume":"17","author":"Sid","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182638","article-title":"Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study","volume":"295","author":"Yu","year":"2024","journal-title":"J Intern Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05714-y","article-title":"Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00889","article-title":"Combination lenalidomide and azacitidine: A novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282570","article-title":"Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial","volume":"108","author":"Schroeder","year":"2023","journal-title":"Haematologica"},{"key":"B70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid Malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1761964","article-title":"Venetoclax is safe and efficacious in relapsed\/refractory AML","volume":"61","author":"Ganzel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid Malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1638176","article-title":"Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Cheng","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.005","article-title":"Hypomethylating agents and venetoclax for acute myeloid leukemia relapsed after hematopoietic stem cell transplant","volume":"24","author":"Ionescu","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41408-021-00437-z","article-title":"Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation","volume":"11","author":"Joshi","year":"2021","journal-title":"Blood Cancer J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2025.100550","article-title":"Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification","volume":"24","author":"Sun","year":"2025","journal-title":"Leuk Res Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1182\/blood-2024-193723","article-title":"Outcomes with venetoclax and hypomethylating agents in relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"144","author":"Shahzad","year":"2024","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2026.300534","article-title":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax","author":"Goldfinger","year":"2026","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025834","article-title":"A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort","volume":"144","author":"Goldfinger","year":"2024","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-0842","article-title":"A metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients","volume":"15","author":"Willekens","year":"2025","journal-title":"Blood Cancer J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1200\/jco.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.44","article-title":"IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation","volume":"8","author":"Caillet","year":"2024","journal-title":"Hemasphere"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s2152-2650(25)01623-4","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00426-7","article-title":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee","volume":"26","author":"Sanz","year":"2025","journal-title":"Lancet Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.011","article-title":"Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia","volume":"25","author":"Schroeder","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study)","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1452611","article-title":"The current and future role of stem cells in myelodysplastic syndrome therapies","volume":"11","author":"Kobbe","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-026-02845-w","article-title":"IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms","volume":"61","author":"Richardson","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022273","article-title":"Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms","volume":"144","author":"Scheid","year":"2024","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106997","article-title":"Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome","volume":"124","author":"Zhang","year":"2023","journal-title":"Leuk Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"767.e1","DOI":"10.1016\/j.jtct.2022.08.008","article-title":"Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: Results of a systematic review and meta-analysis","volume":"28","author":"Kharfan-Dabaja","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","article-title":"Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: An EBMT registry analysis of 1540 patients","volume":"14","author":"Schm\u00e4lter","year":"2024","journal-title":"Blood Cancer J"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01777-5","article-title":"Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: A prospective multicenter phase II trial","volume":"57","author":"Finke","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:41:55Z","timestamp":1784695315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1895791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2026.1895791"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1895791","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1895791"}}